Aandeel ARPO AERPIO PHARMACEUTICALS
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren
Inactief instrument

Andere talen Aerpio Pharmaceuticals

Aandelen

ARPO

US00810B1052

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)
UPDATE – Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)
Aerpio Pharmaceuticals : Aadi Bioscience to Participate in H.C. Wainwright’s 2nd Annual Precision Oncology Conference 2021
Aadi Bioscience Completes Merger With Aerpio Pharmaceuticals; Shares Decline on Nasdaq Debut
AADI BIOSCIENCE, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Amendment or Waiver to Code of Ethics, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
Aerpio Pharmaceuticals, Inc.(NasdaqCM:ARPO) dropped from NASDAQ Composite Index
Aerpio Pharmaceuticals : Aadi Bioscience Corporate Overview
Aadi Bioscience, Inc. completed the acquisition of Aerpio Pharmaceuticals, Inc. in a reverse merger transaction.
Aerpio Pharmaceuticals : ASSET PURCHASE AGREEMENT (Form 8-K)
AERPIO PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
Aerpio Pharmaceuticals : Submission of Matters to a Vote of Security Holders (Form 8-K)
AERPIO PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AERPIO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Aerpio Pharmaceuticals : Reports Second Quarter 2021 Financial Results and Provides Business Update (Form 8-K)
Aerpio Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
Aerpio Pharmaceuticals : Reports Second Quarter 2021 Financial Results and Provides Business Update
Aerpio Pharmaceuticals : Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO™ for the Treatment of Advanced Malignant PEComa (Form 8-K)
AERPIO PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
North American Morning Briefing : Stock Futures -3-
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers ARPO
  4. Nieuws Aerpio Pharmaceuticals
  5. Andere talen